Scholarlink

<p>Deep brain stimulation (DBS) is established for Parkinson’s disease (PD), but conventional DBS (cDBS) may yield suboptimal symptom control and side effects, particularly on gait. Adaptive DBS (aDBS), adjusting stimulation to subthalamic beta activity, may offer superior outcomes, though programming remains incompletely defined. Between January and April 2025, we offered dual threshold aDBS to 20 consecutive PD patients with chronic cDBS and a Percept neurostimulator. Nine were eligible; exclusions were due to signal artifacts, absence of a distinct beta peak, or stimulation settings incompatible with aDBS. By July 2025, five remained on chronic aDBS, one reverted to cDBS by preference, and three were still in optimization. In this manuscript, we outline our aDBS programming principles and preliminary clinical efficacy. On unblinded MDS-UPDRS III, aDBS yielded a ~35% greater motor improvement than cDBS, with gait showing the most consistent benefits. Dual threshold aDBS appears clinically advantageous, though current technical and programming constraints may limit widespread adoption.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chronic adaptive deep brain stimulation in Parkinson’s disease: ADAPT-START findings and programming principles

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Simona Cascino,
  • Fabrizio Luiso,
  • Laura Caffi,
  • Chiara Palmisano,
  • Elena Contaldi,
  • Gianni Pezzoli,
  • Ioannis Ugo Isaias,
  • Salvatore Bonvegna

摘要

Deep brain stimulation (DBS) is established for Parkinson’s disease (PD), but conventional DBS (cDBS) may yield suboptimal symptom control and side effects, particularly on gait. Adaptive DBS (aDBS), adjusting stimulation to subthalamic beta activity, may offer superior outcomes, though programming remains incompletely defined. Between January and April 2025, we offered dual threshold aDBS to 20 consecutive PD patients with chronic cDBS and a Percept neurostimulator. Nine were eligible; exclusions were due to signal artifacts, absence of a distinct beta peak, or stimulation settings incompatible with aDBS. By July 2025, five remained on chronic aDBS, one reverted to cDBS by preference, and three were still in optimization. In this manuscript, we outline our aDBS programming principles and preliminary clinical efficacy. On unblinded MDS-UPDRS III, aDBS yielded a ~35% greater motor improvement than cDBS, with gait showing the most consistent benefits. Dual threshold aDBS appears clinically advantageous, though current technical and programming constraints may limit widespread adoption.